Dr. Brady has over 30 years experience across the spectrum of scientific research, education and drug commercialization. He received his PhD in Anatomy and Cell Biology from the University of Iowa and honed his research technical and writing skills during his postdoctoral training at the City of Hope. With a research interest in primate neuroanatomy, Dr. Brady joined the Institute for Biogerontology Research in Sun City, AZ to initially help and then manage the Human Brain and Nervous System Tissue Bank. At the same time his RO1 grant was funded by the National Institute on Aging (NIA), NIH, he was invited to join the Laboratory of Neurosciences at NIA where he developed and supervised a Molecular Neuropathology Unit, and continued his Human Brain Banking efforts to support intra-institute research efforts. During his 6-year tenure at NIH he also held an Adjunct Associate Professor of Anatomy position at the Uniformed Services University of the Health Sciences. Dr. Brady left NIH to join the Department of Oral Biology, Indiana University School of Dentistry to help their transition from a lecture-based to a problem-based teaching curriculum. After 3 successful years of improving the School's ranking in the Anatomical Sciences Section of Part 1 of the Dental National Boards, Dr. Brady was invited to consider a role in Global Regulatory Affairs at Eli Lilly and Company (Lilly). During his 17 years at Lilly, Dr. Brady supported drug development and marketing approvals is the areas of metabolic and endocrine disorders as well as oncology. He developed expertise in regulatory affairs with regard to rare diseases and rational drug development such that Lilly sent him to China and Mexico to educate their Regulatory Reviewers. Upon retiring from Lilly, Dr. Brady worked for Fortress Biotech, Inc to help set up a Regulatory Function and provide consistent regulatory strategy advice across the Fortress subsidiary companies. After 6 months, a change in focus at Fortress facilitated the transition back to graduate education where he now serves as a part-time Graduate Student Advisors in the Medical and Molecular Genetics Department. Dr. Brady continues to provide global regulatory strategy advice in oncology, cell and gene therapy and multiple rare disease applications.